1. SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses.
- Author
-
Straus MR, Kinder JT, Segall M, Dutch RE, and Whittaker GR
- Subjects
- Animals, Cell Line, Cell Survival drug effects, Hemagglutinin Glycoproteins, Influenza Virus metabolism, Host-Pathogen Interactions, Humans, Influenza A Virus, H1N1 Subtype drug effects, Influenza A Virus, H1N1 Subtype growth & development, Influenza A Virus, H1N1 Subtype metabolism, Influenza A Virus, H1N1 Subtype physiology, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype growth & development, Influenza A Virus, H3N2 Subtype metabolism, Influenza A Virus, H3N2 Subtype physiology, Influenza A Virus, H7N9 Subtype drug effects, Influenza A Virus, H7N9 Subtype growth & development, Influenza A Virus, H7N9 Subtype metabolism, Influenza A Virus, H7N9 Subtype physiology, Influenza A virus growth & development, Influenza A virus metabolism, Influenza A virus physiology, Membrane Glycoproteins genetics, Metapneumovirus growth & development, Metapneumovirus metabolism, Metapneumovirus physiology, Peptide Hydrolases metabolism, Protease Inhibitors pharmacology, Recombinant Proteins pharmacology, Serine Endopeptidases metabolism, Serine Proteinase Inhibitors metabolism, Trypsin Inhibitors metabolism, Trypsin Inhibitors pharmacology, Influenza A virus drug effects, Membrane Glycoproteins metabolism, Membrane Glycoproteins pharmacology, Metapneumovirus drug effects, Serine Proteinase Inhibitors pharmacology, Viral Fusion Proteins metabolism
- Abstract
Viruses possessing class I fusion proteins require proteolytic activation by host cell proteases to mediate fusion with the host cell membrane. The mammalian SPINT2 gene encodes a protease inhibitor that targets trypsin-like serine proteases. Here we show the protease inhibitor, SPINT2, restricts cleavage-activation efficiently for a range of influenza viruses and for human metapneumovirus (HMPV). SPINT2 treatment resulted in the cleavage and fusion inhibition of full-length influenza A/CA/04/09 (H1N1) HA, A/Aichi/68 (H3N2) HA, A/Shanghai/2/2013 (H7N9) HA and HMPV F when activated by trypsin, recombinant matriptase or KLK5. We also demonstrate that SPINT2 was able to reduce viral growth of influenza A/CA/04/09 H1N1 and A/X31 H3N2 in cell culture by inhibiting matriptase or TMPRSS2. Moreover, inhibition efficacy did not differ whether SPINT2 was added at the time of infection or 24 h post-infection. Our data suggest that the SPINT2 inhibitor has a strong potential to serve as a novel broad-spectrum antiviral., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF